Mather Group
NBIX icon

Mather Group’s Neurocrine Biosciences NBIX Stock Holding History

Mather Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.4K Buy
186
+28
+18% +$4.5K ﹤0.01% 1361
2026
Q2 		$26.6K Hold
158
– – ﹤0.01% 1266
2026
Q1 		$20.8K Buy
+158
New +$21K ﹤0.01% 1267
2025
Q4 		– Sell
-168
Closed -$23.6K – 1288
2025
Q3 		$23.6K Buy
+168
New +$22.8K ﹤0.01% 1079
2025
Q2 		– Sell
-193
Closed -$21.3K – 1321
2025
Q1 		$21.3K Hold
193
– – ﹤0.01% 1083
2024
Q4 		$26.3K Hold
193
– – ﹤0.01% 1015
2024
Q3 		$22.2K Sell
193
-39
-17% -$5.35K ﹤0.01% 1043
2024
Q2 		$31.9K Buy
232
+34
+17% +$4.66K ﹤0.01% 1131
2024
Q1 		$26K Buy
+198
New +$27K ﹤0.01% 999

Other funds holding NBIX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
PKO BP Bankowy Universal Pension Society
PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Mather Group's NBIX Position: Q3 2026 in Review

Mather Group increased its Neurocrine Biosciences (NBIX) stake by 18% in Q3 2026, buying an estimated $4.5K and bringing the position to 186 shares worth $26.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Mather Group first reported a position in NBIX in Q1 2024 and has held it in 9 quarters since. The position peaked at $31.9K in Q2 2024. 132 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Mather Group held 186 shares of Neurocrine Biosciences worth $26.4K as of Q3 2026.
  • Mather Group bought 28 Neurocrine Biosciences shares in Q3 2026, an estimated $4.5K.
  • Neurocrine Biosciences made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1361 holding.
  • Mather Group first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 9 quarters since.
  • Mather Group's Neurocrine Biosciences position peaked at $31.9K in Q2 2024.
  • 132 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.